Chromosome abnormalities account for half of the recorded miscarriages. Data from cytogenetic analysis of the products of conception (POC) in miscarriages are reviewed in the paper. Genetic analysis of POC allows patients to be given prognostic information. Molecular genetic techniques can overcome the pitfalls of conventional karyotyping, such as culture failure and trace submicroscopic abnormalities. We compare the pros and cons when these technologies are applied to the analysis of POC after miscarriage. Guidance is also provided for future clinical applications. The objective of the review is to help clinicians understand the limitations and to optimise the usefulness of genetic analysis of POC.
Introduction
Miscarriage is the most frequent complication of pregnancy. It is defined as a pregnancy loss before 20 weeks of gestation. Clinically recognised pregnancy loss occurs in about 15% of pregnancies in women under the age of 35 years. Most of the losses are 'spontaneous' miscarriages in the first trimester, which appear to occur at random. This is in contrast to recurrent miscarriage, or recurrent pregnancy loss (RPL), which can be defined as three consecutive pregnancy losses before 20 weeks of gestation. 1 Epidemiological studies have revealed that 1-2% of women experience RPL, 2 representing approximately 1 in 300 pregnancies. 1 There are several recognised causes for recurrent miscarriage, namely: structural uterine anomalies; endocrine disorders; prothrombotic conditions, such as antiphospholipid syndrome; and balanced translocation involving one of the parents. Regardless of whether the miscarriage is spontaneous or recurrent, the couples involved will want to know whether there is an explanation for the miscarriage. Consequently, the question of the cytogenetic study of products of conception (POC) to determine whether the miscarriage was a result of chromosomal aberration may be raised. The desire to conduct cytogenetic studies of POC may also influence the choice of management options of the miscarriage. Nevertheless, the cytogenetic examination of the POC is rather controversial in several respects, including the indication, the prognostic value, and the debate that it will soon be replaced by modern molecular genetic tests, such as fluorescence in situ hybridisation, array-based comparative genomic hybridisation, next-generation sequencing, etc. In this article, the laboratory and clinical aspects of the cytogenetic study of POC will be reviewed.
Methods
A search for original articles published from January 2000 up to January 2016 was performed using PubMed and Google Scholar, which identified a total of 107 studies on the genetic etiology of POC in miscarriages. The following terms were used: 'abortion, spontaneous' or 'miscarriage', 'abortion, habitual' or 'recurrent miscarriage', 'in vitro fertilisation' or 'IVF' or 'intracytoplasmic sperm' or 'ICSI' and 'product of conception', and 'karyotyping' or 'cytogenetic'.
The articles identified were restricted to English language full-text papers. We have selected publications that provided information on the relevant sections of the review. For example, publications that did not mention the culture failure rate were not included in the section on culture failure in POC.
Results

Spontaneous miscarriage and recurrent miscarriage
The results of conventional cytogenetic analysis of the karyotype of POC in spontaneous miscarriage are summarised in Table S1 . [3] [4] [5] [6] [7] [8] Approximately 50% of spontaneous miscarriages are a result of fetal aneuploidy (pooled prevalence 49.7%; 95% confidence interval, 95% CI 34.9-64.6%). Among those with aneuploidy, the anomalies in descending order of frequency are: trisomy (51.9%); polyploidy (18.8%); monosomy (15.2%); structural abnormalities (6.5%); and others (7.6%). The latter group includes mosaics, double, triple and quadruple trisomy, and combined anomalies, including a numeric abnormality together with a structural abnormality. The incidence of cytogenetic abnormality in POC from women with recurrent miscarriage is summarised in Table S2 . Surprisingly, less than half (40.4%; 95% CI 25.2-55.7%) of all successful karyotyped miscarriage samples showed an abnormal karyotype. This suggests that aneuploidy is more likely to be the cause of spontaneous miscarriage than recurrent miscarriage. It also indirectly suggests that non-genetic factors play a more important role in recurrent miscarriage.
Miscarriages following assisted reproductive technology treatment
The results of conventional cytogenetic analysis of the karyotype of POC in miscarriages following assisted reproductive technology (ART) treatment are reviewed in Table S3 . [9] [10] [11] [12] [13] The abnormality rate is 53.0% (95% CI 44.8-61.3%), which is similar to that observed in spontaneous miscarriage (49.7%). In a meta-analysis carried out by Qin et al., 14 it was found that the frequency of chromosomal abnormality in early spontaneous miscarriages after ART was not significantly increased compared with those in natural conceptions. In addition, the frequency of chromosomal abnormality in early spontaneous miscarriages following in vitro fertilisation (IVF) was similar to those observed following ICSI.
Types of genetic abnormalities
The pattern of chromosomal abnormalities in POC from spontaneous miscarriage, recurrent miscarriage, and following ART treatment are shown in Tables S1-S3. The pooled results show that numerical abnormalities constitute~90% of all those with abnormal results (autosome trisomies, 60%; polyploidies,~15%; and X chromosome monosomy, 15%). Structural abnormalities constitute~4% and other abnormalities constitute~6%.
It has been observed that the different types of chromosomal abnormality are associated with different clinical scenarios. The frequency of trisomies, which result from meiotic non-disjunction during gametogenesis, increases with maternal age. All trisomies have been observed in miscarriages, except for chromosome 1. The most frequent type is trisomy 16, representing around 30% of all trisomies, 15 followed by trisomy 22, trisomy 21, and trisomy 15, in descending order (Table S4 ). Polyploidy is considered to be a consequence of abnormal fertilization, however, and is not related to maternal age. 16 The abnormality most frequently resulting from abnormal fertilisation is triploidy. Autosomal monosomies are very rare in human miscarriages; however, monosomy X is frequently found. For the structural abnormalities group, the abnormalities are mainly translocations and inversions. About half of the number in this group result from karyotype abnormalities in one of the parents. Translocations are found in 5% of couples experiencing repeated losses. 
Maternal age
So far, advanced maternal age remains the only aetiological risk factor identified for chromosome aneuploidy. 18 When compared with spontaneous miscarriage, recurrent miscarriage exhibited a decrease in viable trisomies (chromosomes 13, 18, and 21) and an increase in non-viable trisomies in women aged >35 years, together with an increase in unbalanced structural anomalies (29.0 versus 4.9%) in younger women. This result indicated that the most commonly observed chromosomal anomaly type in recurrent miscarriage depends on maternal age: non-viable autosomal trisomies in older women and unbalanced structural anomalies in younger women.
Gestational age
The proportion of chromosomal anomalies found in POC also varies with the gestational age of the pregnancy. One study reported that the proportion of abnormal karyotyping results found before the detection of a fetal heartbeat (45%) was significantly higher than that found in later losses (21%). 19 In another study, the reported rates of chromosomal abnormalities were up to 90% in embryonic specimens,~50% for losses that occurred at 8-11 weeks of gestation,~30% for losses that occurred at 16-19 weeks of gestation,~10% for losses that occurred after 20 weeks of gestation, and 6-12% in stillbirths that occurred at or beyond 20 weeks of gestation. 20 In addition, it was observed that submicroscopic chromosomal changes were more commonly encountered in late losses.
Number of previous miscarriages and prognostic value
Ogasawara et al. 21 analysed POC from 1309 women with a history of between two and 20 consecutive first-trimester miscarriages using standard G-banding (Giemsa banding is a cytogenetic technique to produce a visible karyotype by staining condensed chromosomes), and found that the frequency of normal embryonic karyotypes increased as the number of previous miscarriages increased. The finding is consistent with the notion that as the number of previous miscarriages increases, the fetal contribution to the losses becomes less important or less likely, whereas the maternal or uterine contribution to the losses becomes more important.
Nevertheless, the finding of aneuploidy in a given miscarriage is associated with a better outcome for a subsequent pregnancy. 22 
Limitations of karyotyping
Culture failure As shown in Tables S1 and S2, the pooled culture failure rate for both spontaneous and recurrent miscarriage is around 20%. The high chance of culture failure may be caused by insufficient villi, by the degeneration of villi following a delay in the commencement of the culture process, or by bacterial contamination after incubation. The hypothesis that the proliferative capacity of cells is connected with chromosomal constitution has long been discussed. Apoptosis is increased and cell proliferation is decreased in chromosomally abnormal villi. 23 Maternal cell contamination (MCC) Molecular analysis of 1222 miscarriage specimens from 124 centres revealed a 22% MCC rate overall. 24 
Low resolution
Although karyotyping remains the gold standard to detect chromosome abnormalities in POC, it cannot detect subtle chromosomal anomalies such as microdeletions, microduplications and subtle rearrangements of subtelomeric regions. The resolution of karyotyping is limited to a chromosomal segment of more than 3-5 Mb.
Detection of mosaicism
The mosaic rate of miscarriage derived from the culture of villi from POC varies, but is considered to be less than 1%. The mosaic rate of miscarriage derived from placental tissue is considerably higher. It is possible that karyotyping underestimates mosaicism because the standard analysis of 10-15 cells may not detect low-level (<15-20%) mosaicism.
Time consuming
The karyotyping procedure usually takes 10-21 days to get a result.
Fluorescence in situ hybridisation
Fluorescence in situ hybridisation (FISH) is a technique that uses fluorescent probes that bind to only those parts of the chromosome with a high degree of sequence complementarity. FISH analyses are important in the clinical diagnosis of various chromosomal abnormalities, including deletions, duplications, and translocations. Nowadays, multi-fluor FISH, in which each chromosome appears to be painted with a different colour, can quickly scan a set of chromosomes with limited resolution. In practice it is unusual to use the complete set of 24 probes; instead, between five and seven probes are selected for the chromosomes most commonly involved in aneuploidy (for example 13, 14, 15, 16, 18, 21, 22 , and X). The resolution of FISH is 40-250 kb per probe for a single site.
Advantages of FISH:
It is possible to analyse interphase chromosomes with FISH, as well as the metaphase chromosomes used in karyotyping, which eliminates the requirement for cell culture.
It is possible to simultaneously monitor multiple sites if the hybridisation probes have been labelled with different flurophores.
FISH gives quick results (in 1-2 days). FISH offers high specificity. Most clinical FISH assays have an analytic specificity of greater than 98%. 25 
Disadvantages of FISH:
The ability of FISH to detect chromosomal anomalies is limited by the number of probes selected. A normal result infers only that the specific chromosomes (segments) scrutinised by the probes are normal, and does not give information on the other chromosomes, which have not been targeted for scrutiny.
Manual scoring and signal enumeration may be difficult, because of the truncation of nuclei on tissue sections and overlapping of nuclei. Special training in cytogenetic laboratory techniques is required.
FISH cannot detect some structural chromosomal abnormalities (e.g. inversions).
Currently, the major role of FISH is in situations when karyotyping analysis is not possible or available. An earlier study showed that in cases of culture failure, precluding karyotyping in spontaneous miscarriage, FISH analysis using probes specific for chromosomes 13, 16, 18, 21, X, and Y was successful in 97% of cases. 26 
Array-based comparative genomic hybridisation
Array-based comparative genomic hybridisation (aCGH) is based on the use of differentially labelled test and reference genomic DNA samples that are simultaneously hybridised to DNA targets arrayed on a glass slide or other solid platform. 27 It is a powerful molecular cytogenetic technique for quickly scanning through an entire genome for imbalances. The resolution of array CGH ranges from oligonucleotides (25-80 bp) to bacterial artificial chromosomes (BACs; 80-200 kb).
Advantages of aCGH: It can detect most types of chromosomal imbalances including submicroscopic imbalances throughout the entire genome.
Time saving: the results may be available in just a few days instead of a few weeks, as is the case with conventional cytogenetic analysis that requires cell culture.
No tissue culture failure and MCC. It is possible to examine archival formalin-fixed and paraffin-embedded POC tissues.
It may detect pathogenic DNA copy number variants (CNVs). One study used aCGH to investigate 40 POC samples in first-trimester miscarriages with a normal karyotyping result. 28 In total, 45 CNVs with size ranging from 120 kb to 4.3 Mb were identified in 31 samples. Thirty-one CNVs were considered as common and 14 were considered unique, of which six genes and five microRNAs may be related to miscarriage.
Disadvantages of aCGH: It cannot detect balanced chromosome abnormalities or some polyploidies (e.g. tetraploidy), which constitute 10-15% of all abnormalities present in POC.
Sometimes, the findings of aCGH fall into the category of variant of unknown significance (VOUS), which means that the clinical significance of the observed change is uncertain.
It is more expensive than a conventional cytogenetic test.
The results need to be analysed by professional bioinformatics expertise and interpreted by genetics specialists.
A summary of studies on the accuracy of aCGH compared with conventional karyotyping of POC samples from miscarriages is shown in Table S5 . 5, [29] [30] [31] [32] The pooled failure rate of aCGH was only 2.7% (95% CI 0.0-9.0%), much lower than in conventional karyotyping. Approximately 9% of all abnormalities were missed by karyotyping, but they were detected by aCGH. The increased detection rate makes aCGH a better diagnosis tool.
Next-generation sequencing
Sequencing technologies include a number of methods that are grouped broadly to include template preparation, sequencing, and imaging, as well as data analysis. The unique combination of specific protocols distinguishes one technology from another and determines the type of data produced from each platform. The first-generation sequencing is Sanger-based, non-high-throughput DNA sequencing, whereas the next-generation sequencing (NGS) refers to a high-throughput platform to sequence millions or billions of DNA strands in parallel, obviating the need for the fragment-cloning methods. 33 NGS offers singlenucleotide resolution.
Advantages for NGS: A tiny (nanogram) quantity of tissue is sufficient for NGS, eliminating the reliance on polymerase chain reaction (PCR) amplification.
It scrutinises the entire genome, including promoters, exons, non-coding RNAs (ncRNAs), and enhancers.
Disadvantages for NGS:
The technology is still expensive. It costs~$1000 for each sample to be analysed; however, it permits the parallel analysis of multiple samples in a single sequencing run, 34 and could therefore reduce costs when multiple samples are tested.
It requires data processing steps and bioinformatics. It is debatable whether NGS can ever replace traditional cytogenetic analysis in the study of POC, not so much because of the cost, but because of necessity. NGS generates a huge volume of data that requires bioinformatics for interpretation, whereas cytogenetic analysis appears to be good enough to answer a simple clinical question relating to the miscarriage. Almost certainly, NGS will remain a research tool in the study of miscarriage in the near future.
International guidelines and clinical implications
There is currently no consensus on when cytogenetic studies should be carried out on POC following miscarriage or recurrent miscarriage.
The Royal College of Obstetricians and Gynaecologists (RCOG) recommend that 'Cytogenetic analysis should be performed on the POC of the third and subsequent consecutive miscarriage(s)'. 35 If the result is normal, parental karyotyping of the peripheral blood is deemed unnecessary because the likelihood of either one of the parents having balanced translocation is rather unlikely. In this way, not only will the cytogenetic test (of the POC) provide reassurance that the index miscarriage is unrelated to any chromosomal abnormality, but it will also avoid unnecessary cytogenetic analysis of the couple, and this will have financial savings (estimated £300). If cytogenetic testing of the POC showed abnormal results, however, this should be followed-up with formal peripheral blood testing for both parents to verify whether the observed abnormality was sporadic or inherited from the male of female partner. It is therefore logical that every effort should be made to arrange the cytogenetic study of POC in women undergoing a third consecutive miscarriage.
If cytogenetic testing of POC is not available, however, a peripheral blood test for the karyotyping of both partners should be considered, unless they have had a normal live birth previously. In this situation, as in the case of normal findings for POC, the likelihood of any balanced translocation involving either partner is very low indeed.
In 2006, on the other hand, the European Society of Human Reproduction and Embryology (ESHRE) guideline for recurrent miscarriage suggested that the utility of genetic testing of POC after one spontaneous miscarriage is uncertain, and needs to be investigated prospectively in large populations. 36 This guideline is currently being updated.
As for women who have had their second miscarriage, in 2012 the American Society for Reproductive Medicine (ASRM) committee opinion stated that 'The assessment should include the peripheral karyotype analysis of the parents and the POC'. 37 Following assisted conception with pre-implantation genetic diagnosis (PGD) for specific translocations, with the transfer of unaffected embryos or the use of donor gametes, the guideline also recommended an evaluation of whether the miscarriage was random or the result of a treatment failure. The committee emphasised that the genetic testing of POC may be of psychological value to the couple.
The American Congress of Obstetricians and Gynecologists (ACOG) issued guidance on genetic testing for intrauterine fetal demise or stillbirth occurring in the third trimester. 38 They suggested chromosome microarray analysis on fetal tissue in these two types of situation because it identifies additional clinically significant abnormalities in approximately 6% of fetuses with ultrasonography abnormalities and a normal conventional karyotype. In the case of intrauterine death (IUD) occurring in the second trimester, there is as yet no guidance on what constitutes the best genetic test to choose. The ACOG stated that chromosomal microarray analysis to evaluate second-trimester pregnancy losses is not recommended at this time. Nevertheless, as second-trimester loss is unlikely to be a consequence of aneuploidy or balanced translocation, 39 karyotyping is of limited use; if genetic testing is considered desirable, microarray analysis is more likely to be informative as it can detect subtle genetic abnormalities, as in the case of third-trimester loss.
There are several recommendations for clinicians. Firstly, the POC should be obtained as soon as feasible, once a diagnosis of miscarriage has been confirmed and a decision has been made to conduct cytogenetic study for the POC. Secondly, the tissue should be washed gently with normal saline solution to remove maternal blood. Traditionally, gynaecologists have been taught to divide the POC into two parts, one for histological analysis and the other for cytogenetic study. It has been usual practice to put the POC into normal saline solution: the villi can be recognised floating on top of the solution, collected, and sent for cytogenetic study, whereas the portion that remains at the bottom of the solution should be dispatched to the histopathology laboratory. Thirdly, the tissue should be dispatched to the cytogenetic laboratory as soon as possible. Once the POC tissue has been removed from the uterus, its viability will decrease, which may compromise the likelihood of a successful culture. We recommend that the cytogenetic laboratory, having carefully selected sufficient villi tissue for culture, store the remaining part of the specimen at À80°C. In the case of culture failure or a failure to obtain a conclusive result with traditional karyotyping analysis, the tissue can be retrieved for FISH or molecular genetic testing if so desired.
Given the significant rate of culture failure and maternal contamination with routine karyotyping, there is an increasing move towards the use of molecular diagnostic method, which is associated with a lower failure rate.
Conclusion
The karyotyping of POC is informative and should remain the method of choice to obtain genetic information on the underlying cause of recurrent miscarriage. The value of karyotyping of POC in spontaneous miscarriage has yet to be established. There is an increasing trend to use a molecular genetics approach in examining the POC in women with recurrent miscarriage, but this should not yet replace karyotyping. Molecular genetic testing can detect microdeletions, microduplications, and subtle rearrangements of subtelomeric regions, and may be particularly useful for late losses, in which the nature of the chromosomal anomaly is likely to be more subtle.
We recommend an integrated approach, with the use of conventional karyotyping as the first line of investigation and molecular genetic testing as an alternative choice or back-up option. Carefully planned clinical studies should be performed to determine the clinical relevance of submicroscopic chromosome abnormalities.
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